Rigaku Corporation, a global leader in X-ray analytical equipment and a member of the Rigaku Holdings Group, has officially opened the Rigaku Bioscience Laboratory in Cambridge, Massachusetts.
Rigaku Corporation has begun operating its MoleQlyze technology at the newly opened Rigaku Bioscience Laboratory in Cambridge, Massachusetts. MoleQlyze utilizes Rigaku’s proprietary Electron Density Topography (EDT) technology, which allows for the analysis of biomacromolecules in solution, such as antibodies, protein complexes, and virus particles, revealing their structural and dynamic properties. Rigaku is now accepting inquiries for technology demonstrations and analytical contracts.
Cambridge, located near Boston, is one of the world’s leading hubs for bioscience, home to numerous biopharmaceutical companies and academic institutions. The opening of the Rigaku Bioscience Laboratory in this area strengthens Rigaku’s connection to its existing and potential customers, fostering closer collaboration and feedback.
Rigaku aims for MoleQlyze to support biopharmaceutical R&D, particularly in areas like monoclonal antibody therapeutics and advanced drug delivery systems. The technology is expected to help enhance the understanding of biomacromolecule functions.
Jun Kawakami, President and CEO of Rigaku, commented, “We’re excited to offer MoleQlyze in an easy-to-use format for our customers. Cambridge, with its concentration of pharmaceutical and biomedical innovators, is the ideal location for the Rigaku Bioscience Laboratory. We look forward to driving innovation in biomedical product development.”
Hiroyuki Kanda, Global Product Head of Life Sciences, explained, “MoleQlyze enables visualization of protein molecules in solution, overcoming the challenge of crystallizing biomedical products, which many cannot be crystallized using conventional methods. As MoleQlyze becomes more widely adopted, visualizing molecular structures in solution will become standard practice. Additionally, it integrates seamlessly with existing functional analysis workflows, making it an ideal fit for biomedical product developers.”
Rigaku is committed to expanding its presence in the life sciences sector and continuing to collaborate with customers to deliver groundbreaking innovations.
Rigaku Bioscience Laboratory Address:
SmartLabs, 21 Erie St, Cambridge, MA 02139, USA
For more information about EDT and MoleQlyze, visit: https://edt.rigaku.com
For past EDT news releases, visit: https://rigaku-holdings.com/english/news/edt/
About Rigaku Group
Founded in 1951, the Rigaku Group specializes in advanced X-ray and thermal analysis technologies. With a global presence in over 90 countries and around 2,000 employees, Rigaku supports industries and research organizations worldwide. Its expertise spans a variety of sectors, including semiconductors, electronic materials, batteries, energy, and life sciences. Rigaku remains committed to its mission of supporting new perspectives and improving the world.
